Biliopancreatic diversion shows better biochemical results than conventional therapy in Obese T2DM patients
Some studies have shown that metabolic/bariatric surgery is far more efficient than the traditional pharmacological conservative therapies in achieving and maintaining glycemic control among type 2 diabetic (T2DM) severely obese patients.
However, a recent study suggests biliopancreatic diversion (BPD) should be used with caution as a metabolic procedure in the treatment of T2DM in overweight or class 1 obese patients. The study findings were published in the journal Obesity Surgery on January 10, 2022.1
Previous studies demonstrate that in class 1 obese and overweight patients, bariatric/metabolic surgery is followed by a T2DM remission or by a noticeable improvement of glucose control in a significant number of operated subjects, the results being overall better than those observed in T2DM individuals treated by medical/behavioural therapy.
Dr Gian Franco Adami and his team recently conducted a study to evaluate the long-term anti-diabetic effects of BPD in overweight or class 1 obese T2DM patients and reported results at 10 years after BPD performed in severely non-obese T2DM patients.
For their study, the researchers included 30 T2DM patients with BMI<35 and investigated them at one, five and ten years after BPD. They further compared the results with those of 30 T2DM patients followed for ten years on pharmacological and/or behavioural conventional therapy. They assessed the anthropometric, biochemical, and clinical records for complications.
Key findings of the study:
- Upon analysis, the researchers found a marked reduction in the mean levels of fasting blood glucose (FBG) and serum glycated hemoglobin (HbA1C) at 1 year after BPD.
- They noted that the values remained slightly above the diabetic range throughout the entire follow-up.
- They observed T2DM remission in about 50% of the cases at 5 and 10 years after the operation.
- However, they noted that 16 patients (53%) developed severe BPD-related complications and ten patients had a surgical revision of the operation.
- They also reported death in the BPD group, one patient for malignant lymphoma and two patients after surgical revision.
- Among the control group, they observed no changes in the diabetic status with FBG and HbA1C mean values higher than those recorded in the BPD patients at any follow-up time.
- They also noted that all T2DM subjects of the control group were alive at the end of the 10-year follow-up.
The authors concluded, "Despite satisfactory long-term metabolic outcomes, these data indicate that BPD should be used with caution as a metabolic procedure in the treatment of T2DM in overweight or class 1 obese patients."
For further information:
DOI: https://doi.org/10.1007/s11695-021-05870-4.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.